Cytokinetics Insider Sale — 6,695 Shares Disposed by Director

Rhea-AI Filing Summary

Insider sale disclosed: Dr. Edward M. Kaye, a director of Cytokinetics, Inc. (CYTK), reported a sale of 6,695 shares of the company's common stock on 09/30/2025 at a price of $55.08 per share. After this reported transaction, Dr. Kaye beneficially owned 16,535 shares, held directly. The Form 4 was signed by an attorney-in-fact, John Faurescu. The filing presents a single non-derivative sale and no derivative transactions were reported.

Positive

• Transaction fully disclosed with date, price, and post-transaction holdings reported
• Form 4 includes signature by attorney-in-fact, indicating formal execution of filing

Negative

• Director reduced holdings by 6,695 shares, lowering beneficial ownership to 16,535 shares
• No explanation provided for the sale within the filing (economic or personal reasons not stated)

Insights

Financial Analyst

TL;DR: Director sold 6,695 shares at $55.08, leaving 16,535 shares held; transaction is a disclosed insider sale.

The filing shows a straightforward open-market or similar sale (code S) of 6,695 common shares by a company director on 09/30/2025 at $55.08 per share. The post-transaction beneficial ownership is 16,535 shares held directly. No derivative instruments were reported. For investors, this is a routine insider disposition disclosed under Section 16; it provides transparency about director-level selling but does not alone indicate company financial performance.

Corporate Governance Expert

TL;DR: Governance disclosure appears complete for this single transaction; sale is reported by an attorney-in-fact and signed.

The Form 4 includes required elements: reporting person, issuer and ticker, transaction date, transaction code (S), number of shares sold, sale price, and resulting beneficial ownership. The signature block shows filing was executed by an attorney-in-fact. No amendments or additional explanations accompany the entry. This is a routine governance disclosure of an insider sale with no other governance issues disclosed in this form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		S		6,695	D	$55.08	16,535	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CYTK director Edward M. Kaye report on Form 4?

Dr. Edward M. Kaye reported a sale of 6,695 shares of Cytokinetics common stock on 09/30/2025 at $55.08 per share, leaving 16,535 shares beneficially owned.

What type of transaction was reported on the CYTK Form 4?

The filing shows a non-derivative sale (transaction code S) of common stock; no derivative securities were reported.

Who signed the Form 4 for the CYTK reporting person?

The Form 4 was signed by John Faurescu, attorney-in-fact, on behalf of Dr. Kaye on 09/30/2025.

How many shares did the reporting person own after the transaction?

After the reported sale, the reporting person beneficially owned 16,535 shares directly.

Was any derivative activity reported for CYTK in this Form 4?

No; Table II shows no derivative securities acquired, disposed of, or beneficially owned in this filing.